Wechselwirkungen von Rasagilin

During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result. (Fachinformation zu Amfepramon, Gegenanzeigen)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (Fachinformation zu Amfetamin, Gegenanzeigen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (Fachinformation zu Amfetamin und Dexamfetamin, Gegenanzeigen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

CONTRAINDICATIONS IOPIDINE 1% Ophthalmic Solution is contraindicated for patients receiving monoamine oxidase inhibitor therapy and for patients with hypersensitivity to any component of this medication or to clonidine. (Fachinformation zu Apraclonidin, Gegenanzeigen)

Taking, or within 14 days of stopping, a monoamine oxidase inhibitor (MAOI) [see Drug Interactions (7) ] . (Fachinformation zu Atomoxetin, Gegenanzeigen)

…Precautions (5.2) ] • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [ see Warnings and Precautions (5.5) ] • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [ see Warnings and Precautions (5.7), Drug Interactions (7) ] • Known or suspected gastrointestinal obstruction,… (Fachinformation zu Belladonna und Opium, Gegenanzeigen)

Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. (Fachinformation zu Benzfetamin, Gegenanzeigen)

Rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. (Fachinformation zu Rasagilin, Gegenanzeigen)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (Fachinformation zu Buprenorphin, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma). (Fachinformation zu Buprenorphin und Naloxon, Arzneimittelwechselwirkungen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

The use of monoamine oxidase inhibitors (MAOIs) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. (Fachinformation zu Buspiron, Gegenanzeigen)

…respiratory depression [see Warnings and Precautions ( 5.9 ) ] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment[see Warnings and Precautions ( 5.9 ) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ) / Drug Interactions ( 7 ) ]. (Fachinformation zu Butalbital, Acetylsalicylsäure, Koffein und Codein, Gegenanzeigen)

…Precautions ( 5.2 )] • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions ( 5.10 )] • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.11 ), Drug Interactions ( 7 )] • Known or suspected gastrointestinal obstruction,… (Fachinformation zu Butalbital, Paracetamol, Koffein und Codein, Gegenanzeigen)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Butorphanol, Vorsichtsmaßnahmen)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (Fachinformation zu Carbamazepin, Gegenanzeigen)

Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without carbidopa. (Fachinformation zu Carbidopa, Gegenanzeigen)

DUOPA is contraindicated in patients who are currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective MAO inhibitor. (Fachinformation zu Carbidopa und Levodopa, Gegenanzeigen)

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (Fachinformation zu Carbidopa, Levodopa und Entacapon, Gegenanzeigen)

…because deaths have been reported in this age group [see Warnings and Precautions (5.1)]. patients who are hypersensitive to carbinoxamine maleate or any of the inactive ingredients in Carbinoxamine Maleate Extended-Release Oral Suspension [see Warnings and Precautions (5.4)]. patients who are taking monoamine oxidase inhibitors (MAOI) [see Drug Interactions (7)]. (Fachinformation zu Carbinoxamin, Gegenanzeigen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

• Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ), Drug Interactions ( 7 )]. (Fachinformation zu Codein, Gegenanzeigen)

John’s wort and with cyclobenzaprine. (Fachinformation zu Rasagilin, Gegenanzeigen)

Monoamine oxidase inhibitor therapy (See DRUG INTERACTIONS ). (Fachinformation zu Cyproheptadin, Gegenanzeigen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Taking monoamine oxidase inhibitors (MAOIs). (Fachinformation zu Deutetrabenazin, Gegenanzeigen)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Drug Interactions ]. (Fachinformation zu Dexamfetamin, Gegenanzeigen)

Antihistamines are also contraindicated in the following conditions: Hypersensitivity to dexchlorpheniramine maleate or other antihistamines of similar chemical structure Monoamine oxidase inhibitor therapy (See Drug Interaction section) (Fachinformation zu Dexchlorpheniramin, Gegenanzeigen)

• Concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises [see Drug Interactions ( 7.1 )] . (Fachinformation zu Dexmethylphenidat, Gegenanzeigen)

Rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. (Fachinformation zu Rasagilin, Gegenanzeigen)

Rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. (Fachinformation zu Rasagilin, Gegenanzeigen)

Avoid use of diphenoxylate hydrochloride and atropine sulfate in patients who take MAOIs and monitor for signs and symptoms of hypertensive crisis (headache, hyperthermia, hypertension). (Fachinformation zu Diphenoxylat und Atropin, Arzneimittelwechselwirkungen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

…Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets [ see Drug Interactions… (Fachinformation zu Doxylamin und Pyridoxin, Gegenanzeigen)

However, based on mechanism of action, the use of non-selective MAO inhibitors and linezolid should be avoided as there is a potential for increased blood pressure when taken with NORTHERA. (Fachinformation zu Droxidopa, Arzneimittelwechselwirkungen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors/Serotonin and Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs and MAO inhibitors [see Warnings and Precautions (5.7) ]. (Fachinformation zu Eletriptan, Arzneimittelwechselwirkungen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Fentanyl, Warnhinweise und Vorsichtsmaßnahmen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors / Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during combined use of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [ see Warnings and Precautions (5.7) ]. (Fachinformation zu Frovatriptan, Arzneimittelwechselwirkungen)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of granisetron and other serotonergic drugs. (Fachinformation zu Granisetron, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.3) ] . (Fachinformation zu Hydrocodon, Arzneimittelwechselwirkungen)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon und Chlorphenamin, Arzneimittelwechselwirkungen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon und Homatropin, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors (MAOIs) MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma). (Fachinformation zu Hydrocodon und Ibuprofen, Arzneimittelwechselwirkungen)

The use of hydrocodone bitartrate and acetaminophen tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. (Fachinformation zu Hydrocodon und Paracetamol, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions ( 5.3 )]. (Fachinformation zu Hydromorphon, Arzneimittelwechselwirkungen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor ( 4 ) (Fachinformation zu Rasagilin, Gegenanzeigen)

Die Kombination von Johanniskraut mit Antidepressiva und anderen serotonergen Arzneimitteln erhöht das Risiko eines Serotoninsyndroms. (NCCIH, St. John's Wort)

INBRIJA is contraindicated in patients currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or who have recently (within 2 weeks) taken a nonselective MAO inhibitor. (Fachinformation zu Levodopa, Gegenanzeigen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Levorphanol, Vorsichtsmaßnahmen)

John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor ( 4 ) (Fachinformation zu Rasagilin, Gegenanzeigen)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions (5.7) and Drug Interactions (7.1) ] . (Fachinformation zu Lisdexamfetamin, Gegenanzeigen)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Fachinformation zu Lithium, Warnhinweise und Vorsichtsmaßnahmen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (Fachinformation zu Metaxalon, Arzneimittelwechselwirkungen)

Rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome [see Warnings and Precautions ( 5.2 )] . (Fachinformation zu Rasagilin, Gegenanzeigen)

CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (Fachinformation zu Methyldopa, Gegenanzeigen)

Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor because of the risk of hypertensive crisis [see Drug Interactions (7.1) ]. (Fachinformation zu Methylphenidat, Gegenanzeigen)

John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor ( 4 ) (Fachinformation zu Rasagilin, Gegenanzeigen)

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, avoid use in patients with hypertension or in patients taking monoamine oxidase inhibitors [see Drug Interactions ( 7.1 )] . (Fachinformation zu Metoclopramid, Warnhinweise und Vorsichtsmaßnahmen)

Avoid use of MAO inhibitors or linezolid with midodrine. (Fachinformation zu Midodrin, Arzneimittelwechselwirkungen)

Concomitant use of rasagiline with one of many classes of antidepressants (e.g., SSRIs, SNRIs, triazolopyridine, tricyclic or tetracyclic antidepressants) is not recommended [see Drug Interactions ( 7.5 )]. (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

• Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.9 ) and Drug Interactions ( 7 )]. (Fachinformation zu Morphin, Gegenanzeigen)

Monoamine Oxidase Inhibitors (MAOIs) MAOI (e.g., phenelzine, tranylcypromine, linezolid) interactions with opioids may manifest as serotonin syndrome [see PRECAUTIONS; Drug Interactions ] or opioid toxicity (e.g., respiratory depression, coma [see WARNINGS ]). (Fachinformation zu Nalbuphin, Arzneimittelwechselwirkungen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)] . (Fachinformation zu Naratriptan, Arzneimittelwechselwirkungen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Oliceridin, Arzneimittelwechselwirkungen)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (Fachinformation zu Ondansetron, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.3) ] . (Fachinformation zu Oxycodon, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions ( 5.2)]. (Fachinformation zu Oxycodon und Paracetamol, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (Fachinformation zu Oxymorphon, Arzneimittelwechselwirkungen)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (Fachinformation zu Palonosetron, Warnhinweise und Vorsichtsmaßnahmen)

…respiratory depression ( see WARNINGS ). acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment ( see WARNINGS ). concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days ( see WARNINGS ). known or suspected gastrointestinal obstruction, including paralytic ileus ( see WARNINGS… (Fachinformation zu Paracetamol und Codein, Gegenanzeigen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Pentazocin und Naloxon, Vorsichtsmaßnahmen)

Rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome [see Warnings and Precautions ( 5.2 )] . (Fachinformation zu Rasagilin, Gegenanzeigen)

…coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension, pulmonary hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see PRECAUTIONS, Pregnancy ) • Nursing • Use in combination with other… (Fachinformation zu Phendimetrazin, Gegenanzeigen)

John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor ( 4 ) (Fachinformation zu Rasagilin, Gegenanzeigen)

…cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (Fachinformation zu Phentermin, Gegenanzeigen)

…Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] With glaucoma [see Warnings and Precautions (5.3) ] With hyperthyroidism Taking or within 14 days of stopping a monoamine oxidase inhibitors [see Drug Interactions (7) ] With known hypersensitivity to phentermine, topiramate or any of the excipients in phentermine and topiramate extended-release… (Fachinformation zu Phentermin und Topiramat, Gegenanzeigen)

Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within 14 days [ see Warnings and Precautions (5.16) , Drug Interactions (7.6) ]. (Fachinformation zu Promethazin und Codein, Gegenanzeigen)

Rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. (Fachinformation zu Rasagilin, Gegenanzeigen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (Fachinformation zu Pseudoephedrin, Warnhinweise)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Remifentanil, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (Fachinformation zu Rizatriptan, Arzneimittelwechselwirkungen)

…concomitant use of an antidepressant (e.g., selective serotonin reuptake inhibitors-SSRIs, serotonin-norepinephrine reuptake inhibitors-SNRIs, tricyclic antidepressants, tetracyclic antidepressants, triazolopyridine antidepressants) and a nonselective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as selegiline (Eldepryl) and rasagiline . (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of rasagiline with one of many classes of antidepressants (e.g., SSRIs, SNRIs, triazolopyridine, tricyclic or tetracyclic antidepressants) is not recommended [see Drug Interactions ( 7.5 )]. (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)] . (Fachinformation zu Sumatriptan, Arzneimittelwechselwirkungen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

…suspected paralytic ileus [see Warnings and Precautions (5.12) ] Hypersensitivity to tapentadol (e.g., anaphylaxis, angioedema) or to any other ingredients of the product [see Adverse Reactions (6.2) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Drug Interactions (7) ] Significant respiratory depression ( 4 ) (Fachinformation zu Tapentadol, Gegenanzeigen)

• Taking monoamine oxidase inhibitors (MAOIs). (Fachinformation zu Tetrabenazin, Gegenanzeigen)

Rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome [see Warnings and Precautions ( 5.2 )] . (Fachinformation zu Rasagilin, Gegenanzeigen)

Rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome [see Warnings and Precautions ( 5.2 )] . (Fachinformation zu Rasagilin, Gegenanzeigen)

…concomitant use of an antidepressant (e.g., selective serotonin reuptake inhibitors-SSRIs, serotonin-norepinephrine reuptake inhibitors-SNRIs, tricyclic antidepressants, tetracyclic antidepressants, triazolopyridine antidepressants) and a nonselective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as selegiline (Eldepryl) and rasagiline . (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (Fachinformation zu Valbenazin, Arzneimittelwechselwirkungen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Qelbree is contraindicated in patients: receiving concomitant treatment with monoamine oxidase inhibitors (MAOI), or within 14 days following discontinuing an MAOI, because of an increased risk of hypertensive crisis [see Drug Interactions (7.1) ] . receiving concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic… (Fachinformation zu Viloxazin, Gegenanzeigen)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

• Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs. (Fachinformation zu Ziprasidon, Gegenanzeigen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Decreasing the levodopa dose may lessen or eliminate this side effect ( 5.7 ) (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors may result in increased hypotension. (Fachinformation zu Brimonidin, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors may result in increased hypotension. (Fachinformation zu Brimonidin und Timolol, Arzneimittelwechselwirkungen)

For this reason, prescribers should monitor patients for drowsiness or sleepiness, because some of the events occur well after initiation of treatment with dopaminergic medication. (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

…of Adverse Reactions Due to Drug Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors… (Fachinformation zu Bupivacain, Warnhinweise und Vorsichtsmaßnahmen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. (Fachinformation zu Butalbital und Paracetamol, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

For this reason, prescribers should monitor patients for drowsiness or sleepiness, because some of the events occur well after initiation of treatment with dopaminergic medication. (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Ciprofloxacin or Other CYP1A2 Inhibitors Rasagiline plasma concentrations may increase up to 2 fold in patients using concomitant ciprofloxacin and other CYP1A2 inhibitors. (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Fachinformation zu Carvedilol, Arzneimittelwechselwirkungen)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (Fachinformation zu Chloroprocain, Vorsichtsmaßnahmen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Ciprofloxacin or Other CYP1A2 Inhibitors Rasagiline plasma concentrations may increase up to 2 fold in patients using concomitant ciprofloxacin and other CYP1A2 inhibitors. (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

…with rasagiline, patients should be advised of the potential to develop drowsiness and specifically asked about factors that may increase the risk with rasagiline such as concomitant sedating medications, the presence of sleep disorders, and concomitant medications that increase rasagiline plasma levels (e.g., ciprofloxacin) [see Drug Interactions ( 7.6 )] . (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines. (Fachinformation zu Clemastin, Arzneimittelwechselwirkungen)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (Fachinformation zu Clonazepam, Arzneimittelwechselwirkungen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Ciprofloxacin or Other CYP1A2 Inhibitors Rasagiline plasma concentrations may increase up to 2 fold in patients using concomitant ciprofloxacin and other CYP1A2 inhibitors. (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

…be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (Fachinformation zu Diazepam, Arzneimittelwechselwirkungen)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (Fachinformation zu Dicycloverin, Arzneimittelwechselwirkungen)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (Fachinformation zu Dikaliumclorazepat, Arzneimittelwechselwirkungen)

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines. (Fachinformation zu Diphenhydramin, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

…1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance,… (Fachinformation zu Droperidol, Warnhinweise)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression. (Fachinformation zu Estazolam, Arzneimittelwechselwirkungen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

…Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

…increase the susceptibility to and/or intensity of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory… (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

…Significant Drug Interactions with AFREZZA Antidiabetic agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor blood glucose… (Fachinformation zu Humaninsulin (Normalinsulin), Arzneimittelwechselwirkungen)

Drug Interactions MAO inhibitors should be used with caution in patients receiving hydralazine. (Fachinformation zu Hydralazin, Arzneimittelwechselwirkungen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. (Fachinformation zu Insulin aspart, Arzneimittelwechselwirkungen)

…Degludec Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (Fachinformation zu Insulin degludec, Arzneimittelwechselwirkungen)

…with LEVEMIR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (Fachinformation zu Insulin detemir, Arzneimittelwechselwirkungen)

…Glargine-yfgn Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (Fachinformation zu Insulin glargin, Arzneimittelwechselwirkungen)

Clinically Significant Drug Interactions with LYUMJEV Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (Fachinformation zu Insulin lispro, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Concomitant Use with MAO Inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (Fachinformation zu Isofluran, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Monoamine-oxidase inhibitors: Concomitant administration may potentiate the effects and toxicity of monoamine-oxidase inhibitors. (Fachinformation zu Kokain, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (Fachinformation zu Lidocain, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (Fachinformation zu Mepivacain, Warnhinweise)

Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. (Fachinformation zu Metoprolol, Arzneimittelwechselwirkungen)

Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (Fachinformation zu Metoprolol und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Ciprofloxacin or Other CYP1A2 Inhibitors Rasagiline plasma concentrations may increase up to 2 fold in patients using concomitant ciprofloxacin and other CYP1A2 inhibitors. (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

…Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid,… (Fachinformation zu Nateglinid, Arzneimittelwechselwirkungen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

For this reason, prescribers should monitor patients for drowsiness or sleepiness, because some of the events occur well after initiation of treatment with dopaminergic medication. (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine Oxidase Inhibitors (MAOI) Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly. (Fachinformation zu Promethazin, Arzneimittelwechselwirkungen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

For this reason, prescribers should monitor patients for drowsiness or sleepiness, because some of the events occur well after initiation of treatment with dopaminergic medication. (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (Fachinformation zu Sevofluran, Arzneimittelwechselwirkungen)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (Fachinformation zu Suxamethonium, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (Fachinformation zu Rasagilin, Arzneimittelwechselwirkungen)

Ciprofloxacin or Other CYP1A2 Inhibitors Rasagiline plasma concentrations may increase up to 2 fold in patients using concomitant ciprofloxacin and other CYP1A2 inhibitors. (Fachinformation zu Rasagilin, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions Since the chemical structure of difenoxin hydrochloride is similar to meperidine hydrochloride, the concurrent use of MOTOFEN ® with monoamine oxidase inhibitors may, in theory, precipitate a hypertensive crisis. (Fachinformation zu Difenoxin und Atropin, Arzneimittelwechselwirkungen)

It is theoretically possible, therefore, that the combination of Entacapone Tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. (Fachinformation zu Entacapon, Warnhinweise)

Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (Fachinformation zu Glibenclamid und Metformin, Arzneimittelwechselwirkungen)

Antidepressants: The hypotensive effect of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers. (Fachinformation zu Propranolol, Arzneimittelwechselwirkungen)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (Fachinformation zu Terbinafin, Arzneimittelwechselwirkungen)

It is theoretically possible, therefore, that the combination of Tolcapone tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. (Fachinformation zu Tolcapon, Warnhinweise)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (Fachinformation zu Trihexyphenidyl, Arzneimittelwechselwirkungen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)